Cortexyme Contact Number

All Time Past 24 Hours Past Week Past month Post Your Comments?

Listing Results Cortexyme Contact Number

Company Information – Cortexyme

6 hours ago Cortexyme.com Show details

(415) 910-5717Investor Relations Contact. Cortexyme, Inc. 269 East Grand Ave. South San Francisco, CA 94080 (415) 910-5717. [email protected]cortexyme.com. FAQ. When was Cortexyme incorporated? Lorem ipsum dolor sit amet, consectetur adipiscing elit. In eget bibendum libero. Etiam id velit at enim porttitor facilisis. Vivamus tincidunt lectus at risus pharetra ultrices.

Category: Contact NumberShow more

Cortexyme – Cortexyme is developing treatments for

6 hours ago Cortexyme.com Show details

Cortexyme is a clinical stage biopharmaceutical company pioneering upstream therapeutic approaches designed to improve the lives of patients diagnosed with Alzheimer’s and other degenerative diseases. Cortexyme is currently advancing its lead therapeutic candidate, atuzaginstat (COR388), in the GAIN Trial, an ongoing Phase 2/3 clinical trial

Category: Contact NumberShow more

Cortexyme Inc. Information Cortexyme Inc. Profile

1 hours ago Rocketreach.co Show details

Cortexyme is targeting a specific pathogen found in the brain of Alzheimers patients that causes neurodegeneration and other pathology in animal models. Founded in 2012, the company is headquartered in San Francisco, CA. View Top Employees from Cortexyme Inc.

Category: Contact NumberShow more

Expanded Access Policy – Cortexyme

9 hours ago Cortexyme.com Show details

Contact Information. If you have any questions about our expanded access policy, please ask your physician to contact [email protected]cortexyme.com. We anticipate that we will respond to …

Category: Contact NumberShow more

SEC Filing Cortexyme

9 hours ago Ir.cortexyme.com Show details

(415) 994-0040Number Description. 99.1 Investor Contact: Chris Lowe. Cortexyme, Inc. Chief Financial Officer. [email protected]cortexyme.com . Media Contact: Hal Mackins. For Cortexyme, Inc. [email protected] (415) 994-0040. Cortexyme Announces …

Category: Contact NumberShow more

SEC Filing Cortexyme

9 hours ago Ir.cortexyme.com Show details

(415) 910-5717Cortexyme, Inc. 269 East Grand Ave. South San Francisco, CA 94080. (415) 910-5717. (Name, address including zip code, and telephone number including area code, of agent for service) COPIES TO: Scott M. Iyama, Esq.

Category: Contact NumberShow more

Cortexyme Inc. Email Format cortexyme.com Emails

6 hours ago Rocketreach.co Show details

Cortexyme Inc. Email Format. Cortexyme Inc. uses 4 email formats, with first_initial last (ex. [email protected]cortexyme.com) being used 75.5% of the time. Get Verified Emails for Cortexyme Inc. Employees. Cortexyme Inc.'s Email Format. Percentage.

Category: Contact NumberShow more

Investor Relations Cortexyme

5 hours ago Ir.cortexyme.com Show details

Contact IR; INVESTOR RELATIONS. Corporate Profile. Cortexyme is a clinical stage biopharmaceutical company pioneering upstream therapeutic approaches designed to improve the lives of patients diagnosed with Alzheimer’s and other degenerative diseases. The company is advancing its disease-modifying pivotal GAIN Trial in mild to moderate

Category: Contact NumberShow more

Cortexyme Crunchbase Company Profile & Funding

9 hours ago Crunchbase.com Show details

Cortexyme is a clinical stage pharmaceutical company developing therapeutics based on data supporting a new theory of the cause of Alzheimer's and other degenerative disorders. Cortexyme is targeting a specific, undisclosed pathogen tied to neurodegeneration. The target has been validated in a number of animal models and Cortexyme is currently.

Category: Contact NumberShow more

Cortexyme Inc Company Profile and News Bloomberg …

9 hours ago Bloomberg.com Show details

Company profile page for Cortexyme Inc including stock price, company news, press releases, executives, board members, and contact information

Category: Contact NumberShow more

News – Cortexyme

1 hours ago Cortexyme.com Show details

Events News. Cortexyme to Present at Canaccord Genuity’ s 41st Annual Growth Conference on August 11th. By admin Events, News. Events News. Cortexyme Presents Data Linking P. Gingivalis to Elevated Levels of Phospho-tau217 Reinforcing Evidence of Pathogen as Causative Agent of Alzheimer’s Disease at AAIC 2021.

Category: Contact NumberShow more

Cortexyme, Inc. Centennial CO, South San Francisco CA

7 hours ago Bizapedia.com Show details

CORTEXYME, INC. COLORADO FOREIGN CORPORATION: WRITE REVIEW: Address: 269 East Grand Ave South San Francisco, CA 94080: Registered Agent: C T Corporation System: Filing Date: September 18, 2018: File Number: 20181731184: Contact Us About The Company Profile For Cortexyme,

Category: Contact NumberShow more

Cortexyme Company Profile Office Locations, Competitors

6 hours ago Craft.co Show details

NEW YORK, Feb. 18, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Cortexyme, Inc. ("Cortexyme" or the "Company") (NASDAQ: CRTX). Such investors are advised to contact Robert S. Willoughby at [email protected] or …

Category: Contact NumberShow more

Cortexyme IPOScoop

9 hours ago Iposcoop.com Show details

Disclaimer: A SCOOP Rating (Wall Street Consensus of Opening-day Premiums), is a general consensus taken, at press time, from Wall Street and investment professionals concerning how well an IPO might perform when it starts trading. The SCOOP Rating does not reflect the opinions of anyone associated with IPOScoop.com. The SCOOP ratings should not be taken as investment advice.

Category: Contact NumberShow more

Careers – Cortexyme

4 hours ago Cortexyme.com Show details

Cortexyme is committed to creating a diverse environment and is proud to be an equal opportunity employer. All qualified applicants will receive consideration for employment without regard to race, color, religion, gender, gender identity or expression, sexual orientation, national origin, protected veteran status, disability status or any other characteristic protected by law.

Category: Contact NumberShow more

Tipalti Crunchbase Company Profile & Funding

7 hours ago Crunchbase.com Show details

650-319-8999Founders Chen Amit, Oren Zeev. Operating Status Active. Last Funding Type Secondary Market. Legal Name Tipalti Inc. Hub Tags Unicorn. Company Type For Profit. Contact Email contact@tipalti.com. Phone Number +1 650-319-8999. Tipalti streamlines and automates the way companies make payments to their suppliers, partners, publishers, and crowd.

Category: Contact NumberShow more

Company Cortexyme News, Employees and Funding Information

4 hours ago Topionetworks.com Show details

Cortexyme is developing therapeutics based on data supporting a new theory of the cause of Alzheimer's and other degenerative disorders. Cortexyme is targeting a specific, undisclosed pathogen tied to neurodegeneration and beta amyloid production. The target has been validated in a number of animal models and Cortexyme is currently moving a proprietary small molecule towards human …

Category: Contact NumberShow more

Cortexyme Company Profile: Stock Performance & Earnings

7 hours ago Pitchbook.com Show details

Cortexyme Inc is a clinical-stage biopharmaceutical company developing a disease-modifying therapeutic approach to treat Alzheimer's and other degenerative diseases. Its approach is based on the seminal discovery of the presence of Porphyromonas gingivalis or P. gingivalis, and its secreted toxic virulence factor proteases called gingipains.

Category: Contact NumberShow more

SEC Filing Cortexyme

9 hours ago Ir.cortexyme.com Show details

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number. * This undertaking does not affect any limits Section 102(a) of the National Securities Markets Improvement Act of 1996 ("NSMIA") [Pub. L. No. 104-290, 110 Stat. 3416 (Oct. 11, 1996

Category: Contact NumberShow more

News Releases Cortexyme

4 hours ago Ir.cortexyme.com Show details

News Releases. SOUTH SAN FRANCISCO, Calif. -- (BUSINESS WIRE)--Sep. 27, 2021-- Cortexyme, Inc. (Nasdaq: CRTX), a company advancing a pivotal Phase 2/3 trial in Alzheimer’s disease and a growing pipeline of therapeutics for degenerative diseases, today announced that it will participate at the upcoming 14 th. First participants dosed in

Category: Contact NumberShow more

Cortexyme Employees, Board Members, Advisors & Alumni

6 hours ago Crunchbase.com Show details

Number of Board Member and Advisor Profiles 7 Cortexyme has 7 board members and advisors, including Christopher Senner . Christopher Senner Board Member Mar 2019

Category: Contact NumberShow more

Cortexyme, Inc. (CRTX) Company Profile & Overview Stock

6 hours ago Stockanalysis.com Show details

Cortexyme, Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's disease and other degenerative disorders. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III clinical trial for use in patients with

Category: Contact NumberShow more

Hedge Funds Are Dumping Cortexyme, Inc. (CRTX)

9 hours ago Finance.yahoo.com Show details

The number of bullish hedge fund positions decreased by 5 lately. Cortexyme, Inc. (NASDAQ: CRTX ) was in 3 hedge funds' portfolios at the end …

Category: Contact NumberShow more

Christina Oveis Associate Director of Clinical

9 hours ago Apollo.io Show details

Cortexyme is targeting a specific, undisclosed pathogen tied to neurodegeneration. The target has been validated in a number of animal models and Cortexyme is currently testing several potential lead therapeutics in preclinical studies.

Category: Contact NumberShow more

CORTEXYME AKTIE News Aktienkurs Dividende Chart

7 hours ago Finanzen.net Show details

CORTEXYME AKTIE und aktueller Aktienkurs. Nachrichten zur Aktie Cortexyme Inc Registered Shs A2PHHD CRTX US22053A1079

Category: Contact NumberShow more

Analyzing Cortexyme's Unusual Options Activity

6 hours ago Benzinga.com Show details

Analyzing Cortexyme's Unusual Options Activity. by Benzinga Insights. August 9, 2021 1:09 pm. On Monday, shares of Cortexyme (NASDAQ: CRTX) saw …

Category: Contact NumberShow more

Cortexyme Announces Lead 3CLpro Inhibitor for the

7 hours ago Finance.yahoo.com Show details

SOUTH SAN FRANCISCO, Calif., July 23, 2021--Cortexyme, Inc. (Nasdaq: CRTX), a company advancing a pivotal trial in Alzheimer’s disease with top-line data expected in …

Category: Contact NumberShow more

Chris Lowe CFO Cortexyme, Inc. Business Profile

4 hours ago Apollo.io Show details

Cortexyme is targeting a specific pathogen found in the brain of Alzheimer's patients that causes neurodegeneration and other pathology in animal models. Cortexyme's lead small molecule, atuzaginstat (COR388), has advanced through Phase Ib and is currently the subject of a Phase 2/3 GAIN clinical trial in mild to moderate Alzheimer's disease

Category: Contact NumberShow more

Michael J. Detke Net Worth, Biography & Insider Trading

6 hours ago Insidertrades.com Show details

The estimated net worth of Michael J. Detke is at least $904,200.00 as of August 10th, 2021. Dr. Detke owns 10,000 shares of Cortexyme stock worth more than $904,200 as of September 17th. This net worth approximation does not reflect any other assets that Dr. Detke may own. Learn More.

Category: Contact NumberShow more

Cortexyme to Host TwoPart Key Opinion Leader Webinar

3 hours ago Finance.yahoo.com Show details

SOUTH SAN FRANCISCO, Calif., July 08, 2021--Cortexyme, Inc. (Nasdaq: CRTX), a company advancing a pivotal trial in Alzheimer’s disease with topline data expected in …

Category: Contact NumberShow more

Cortexyme, Inc. Announces Pricing of Initial Public Offering

5 hours ago Finance.yahoo.com Show details

SOUTH SAN FRANCISCO, Calif.-(BUSINESS WIRE)-Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering a novel disease-modifying therapeutic approach to …

Category: Contact NumberShow more

Cortexyme, Inc. (NASDAQ:CRTX) Given Average Recommendation

1 hours ago Marketbeat.com Show details

A number of large investors have recently made changes to their positions in the business. Ameritas Investment Partners Inc. lifted its holdings in Cortexyme by 12.6% in the second quarter. Ameritas Investment Partners Inc. now owns 1,564 shares of the biopharmaceutical company's stock valued at $83,000 after acquiring an additional 175 shares

Category: Contact NumberShow more

Cortexyme to Present at the Stifel 3rd Annual CNS Day on

1 hours ago Finance.yahoo.com Show details

Cortexyme, Inc. (Nasdaq: CRTX), a company advancing a pivotal trial in Alzheimer's disease with topline data expected in the fourth quarter of …

Category: Contact NumberShow more

Cortexyme : Corporate Overview September 2021 MarketScreener

4 hours ago Marketscreener.com Show details

COR588 is a lysine gingipain inhibitor that began Phase 1 study in Q3 2021. Lead arginine gingipain inhibitors, COR788 and COR822, have been selected. Lead 3CLpro inhibitors, COR803 and COR817, for coronavirus treatment have been selected. $153.5M in cash, equivalents, and short-term investments (as of June 30, 2021)

Category: Contact NumberShow more

Christopher P. Lowe Net Worth, Biography & Insider Trading

9 hours ago Insidertrades.com Show details

(650) 910-5717The corporate mailing address for Mr. Lowe and other Cortexyme executives is 269 EAST GRAND AVE, SOUTH SAN FRANCISCO CA, 94080. Cortexyme can also be reached via phone at (650) 910-5717 and via email at [email protected]

Category: Contact NumberShow more

Cortexyme : Presents New Data Demonstrating Evidence of P

8 hours ago Marketscreener.com Show details

Cortexyme, Inc. (Nasdaq: CRTX), a company advancing a pivotal trial in Alzheimer’s disease with top-line data expected by mid-November 2021 and a growing pipeline of therapeutics for degenerative diseases, announced the presentation of new data demonstrating evidence of P. gingivalis infection of the central nervous system in Alzheimer’s disease at the Annual Biomarkers for …

Category: Contact NumberShow more

A Single and Multiple Ascending Dose Study of COR588

7 hours ago Clinicaltrials.gov Show details

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04920903

Category: Contact NumberShow more

Cortexyme : to Present New Data at AAIC 2021 MarketScreener

3 hours ago Marketscreener.com Show details

Cortexyme, Inc. (Nasdaq: CRTX), a company advancing a pivotal trial in Alzheimer’s disease with top-line data expected in the fourth quarter of 2021 and a growing pipeline of therapeutics for degenerative diseases, announced that it will present two poster presentations covering an update from its pivotal Phase 2/3 GAIN Trial of atuzaginstat, in addition to new data demonstrating the

Category: Contact NumberShow more

Noteworthy Friday Option Activity: POST, CRTX, BKNG Nasdaq

4 hours ago Nasdaq.com Show details

021-10-08Contact; Quick Links That number works out to 150.6% of POST's average daily trading volume over the past month, of 403,645 shares. Cortexyme Inc (Symbol: CRTX) saw options trading volume

Category: Contact NumberShow more

CORTEXYME, INC. : Shareholders Board Members Managers and

4 hours ago Marketscreener.com Show details

Cortexyme, Inc. is a clinical stage biopharmaceutical company. The Company is focused on providing disease-modifying therapeutics to treat Alzheimer's and other degenerative diseases. The Company is focused on an infectious pathogen tied to neurodegeneration and chronic inflammation in …

Category: Contact NumberShow more

SEC FORM D

4 hours ago Sec.gov Show details

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number. * This undertaking does not affect any limits Section 102(a) of the National Securities Markets Improvement Act of 1996 ("NSMIA") [Pub. L. No. 104-290, 110 Stat. 3416 (Oct. 11, 1996

Category: Contact NumberShow more

Florian Ermini Associate Director, In Vivo Pharmacology

4 hours ago Linkedin.com Show details

In contrast, in aged, amyloid-depositing APP23 mice, a significant increase in the number of invading ameboid-like GFP-positive cells was found …

Title: Associate Director, In Vivo …
Location: San Francisco Bay
Connections: 344

Category: Contact NumberShow more

What Are Analyst Opinions Regarding Cortexyme Inc. (CRTX

1 hours ago Baxterreport.com Show details

Cortexyme Inc. (CRTX) saw an uptrend of 5.80% in the recent trading with $96.98 being its most recent. The current price level -20.50% lower than the highest price of $121.98 marked by the stock while trading over the past 52-weeks, whereas it is 263.75% higher than the lowest price of $26.66 the company dropped to over past 52-weeks.

Category: Contact NumberShow more

CRTX News Today (Cortexyme) MarketBeat

1 hours ago Marketbeat.com Show details

Cortexyme to Present at Canaccord Genuity' s 41st Annual Growth Conference on August 11th finance.yahoo.com - August 4 at 8:56 AM Cortexyme Presents Data Linking P. Gingivalis to Elevated Levels of Phospho-tau217 Reinforcing Evidence of Pathogen as Causative Agent of Alzheimer's Disease at AAIC 2021 - Business Wire

Category: Contact NumberShow more

Cortexyme Inc. (NASDAQ: CRTX): Can A Stock Be 281.17%

Just Now Marketingsentinel.com Show details

Cortexyme Inc. (NASDAQ:CRTX)’s traded shares stood at 0.33 million during the last session. At the close of trading, the stock’s price was $105.89, to imply an increase of 3.70% or $3.78 in intraday trading. The CRTX share’s 52-week high remains $121.98, putting it …

Category: Contact NumberShow more

Cortexyme : to Host Symposium at AAIC 2021 MarketScreener

1 hours ago Marketscreener.com Show details

Cortexyme, Inc. (Nasdaq: CRTX), a company advancing a pivotal trial in Alzheimer’s disease with top-line data expected in the fourth quarter of 2021 and a growing pipeline of therapeutics for degenerative diseases, announced that it will host a corporate sponsored symposium and dinner held in conjunction with the Alzheimer's Association International Conference® 2021 (AAIC®) taking place

Category: Contact NumberShow more

Pfizer Awards $46M in Financing to Four EaryStage Companies

3 hours ago Genengnews.com Show details

Pfizer today awarded a total of $46 million in financing to four early-stage companies whose specialties align with the pharma giant’s core areas of R&D interest.

Category: Contact NumberShow more

Cortexyme Stock Today CRTX Macroaxis

6 hours ago Macroaxis.com Show details

Cortexyme is trading at 92.00 as of the 1st of October 2021; that is -1.37% down since the beginning of the trading day. The stock's open price was 93.28.Cortexyme has about a 41 percent probability of financial distress in the next few years of operation but had a somewhat good performance during the last 90 days. Equity ratings for Cortexyme are calculated daily based on our scoring framework.

Category: Contact NumberShow more

All Time Past 24 Hours Past Week Past month

Please leave your comments here:

Brand New Updated

Frequently Asked Questions

Who is cortexyme, Inc.and what does it do?

IPO-Edge.com May 8, 2019 SOUTH SAN FRANCISCO, Calif.– (BUSINESS WIRE)–Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering a novel disease-modifying therapeutic...

When to expect cortexyme gain top line data?

The company is advancing its disease-modifying pivotal GAIN Trial in mild to moderate Alzheimer's disease with top-line data expected by mid-November 2021, in addition to growing a proprietary pipeline of first-in-class small molecule therapeutics for Parkinson’s disease, periodontitis, and other diseases with high unmet clinical need.

When to expect cortexyme trial results for Alzheimer's?

August 18, 2021 – SOUTH SAN FRANCISCO, Calif. – Cortexyme, Inc. (Nasdaq: CRTX), a company advancing a pivotal trial in Alzheimer’s… GAIN Trial top-line data for disease modification in Alzheimer’s expected by mid-November 2021 Phase 2 REPAIR sub-study results evaluating periodontal…

Popular Brands

Costco
Cisco
Ccu
Cae